Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Annamaria Brioli, MD, John P. Campbell, PhD, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Graham H. Jackson, MD, Walter Gregory, PhD, Roger G. Owen, MD, J. Anthony Child, MD, Faith E. Davies, MD, Michele Cavo, MD, Mark T. Drayson, MD PhD, Gareth J. Morgan, MD PhD

Blood (2013) 122 (21): 752.

https://doi.org/10.1182/blood.V122.21.752.752

Published: 2013

Journal Articles

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Charlotte Pawlyn, MD, Lorenzo Melchor, PhD, Eileen M Boyle, MD, Annamaria Brioli, MD, Martin F Kaiser, MD, Walter Gregory, PhD, Mark T Drayson, MD PhD, Graham Jackson, MD, Fiona M Ross, DPhil, J. Anthony Child, MD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2013) 122 (21): 529.

https://doi.org/10.1182/blood.V122.21.529.529

Published: 2013

Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD

Blood (2011) 118 (21): 993.

https://doi.org/10.1182/blood.V118.21.993.993

Published: 2011

Journal Articles

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Kevin D Boyd, MD, Fiona M Ross, DPhil, Mark T Drayson, MD, Roger G Owen, MD, Alex J Szubert, MSc, Walter M Gregory, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Graham H Jackson, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1823.

https://doi.org/10.1182/blood.V118.21.1823.1823

Published: 2011

Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 623.

https://doi.org/10.1182/blood.V116.21.623.623

Published: 2010

Journal Articles

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Fiona M. Ross, DPhil, Laura Chiecchio, PhD, GianPaolo Dagrada, BSc, William J Tapper, PhD, Zoe J Konn, BSc, Kan Luk Cheung, BSc, Rebecca KM Protheroe, BSc, David M Stockley, BSc, Susan E Bell, DPhil, Walter M Gregory, PhD, Alexander J Szubert, MSc, Gordon Cook, MD, Roger G. Owen, MD, Mark T. Drayson, MD, Graham Jackson, DM, Faith Davies, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 2980.

https://doi.org/10.1182/blood.V116.21.2980.2980

Published: 2010

Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 311.

https://doi.org/10.1182/blood.V116.21.311.311

Published: 2010

Journal Articles

Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.

Roger G. Owen, MD, J. Anthony Child, MD, Andy C. Rawstron, Phd, Sue Bell, Phd, Kim Cocks, Phd, Faith E. Davies, MD, Graham H. Jackson, MD, Gareth J. Morgan, MD, PhD, Mark T. Drayson, MD

Blood (2007) 110 (11): 1479.

https://doi.org/10.1182/blood.V110.11.1479.1479

Published: 2007

Journal Articles

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Quentin A. Hill, MD, Ruth M. de Tute, MSc, J. Anthony Child, MD, Andy C. Rawstron, PhD, Roger G. Owen, MD

Blood (2006) 108 (11): 3512.

https://doi.org/10.1182/blood.V108.11.3512.3512

Published: 2006

Journal Articles

Rapid and Sensitive Detection of Minimal Plasma Cell Populations Using Six-Colour Flow Cytometry.

Ruth M. de Tute, MSc, Selina J. Denman, BSc, J. Anthony Child, MD, Roger G. Owen, MD, Andy C. Rawstron, PhD

Blood (2006) 108 (11): 3526.

https://doi.org/10.1182/blood.V108.11.3526.3526

Published: 2006

Journal Articles

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

Roger G. Owen, MD, Im Fan, MSc, Sheila J.M. O’Connor, Phd, Faith E. Davies, MD, Rebecca A. Rollett, BSc, J. Anthony Child, MD, Andy C. Rawstron, Phd

Blood (2006) 108 (11): 5051.

https://doi.org/10.1182/blood.V108.11.5051.5051

Published: 2006

Journal Articles

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

David C. Johnson, BSc, Suzanne Grindle, BS, Faith Davies, MD, David Gonzalez, PhD, Christine Ramos, PhD, Kim Hawkins, MSc, Suzanne Bell, PhD, Heather Kesby, BSc, S. Vincent Rajkumar, MD, Erik Rassmusen, PhD, John Crowley, PhD, Emily Blood, PhD, J. Anthony Child, MD, Brian G.M. Durie, MD, Brian G. Van Ness, PhD, Gareth J. Morgan, MDPhD

Blood (2005) 106 (11): 1624.

https://doi.org/10.1182/blood.V106.11.1624.1624

Published: 2005

Journal Articles

Correlation of Serum Free Light Chains and Bone Marrow Plasma Cell Infiltration in Multiple Myeloma.

Graham P. Mead, PhD, Steven D. Reid, PhD, Bradley M. Augustson, MB;BS, Mark T. Drayson, MB;BS, Arthur R. Bradwell, MD, J. Anthony Child, MD

Blood (2004) 104 (11): 4865.

https://doi.org/10.1182/blood.V104.11.4865.4865

Published: 2004

Journal Articles

Long-Term Survival in Patients Receiving Conventional Therapy for Newly Diagnosed Multiple Myeloma; Results from United Kingdom Medical Research Council Trials 1980–1997.

Bradley M. Augustson, MB;BS, Gulnaz Begum, BSc, Gareth J. Morgan, MD, J. Anthony Child, MD, Nicola J. Barth, Janet A. Dunn, PhD, Mark T. Drayson, PhD

Blood (2004) 104 (11): 4921.

https://doi.org/10.1182/blood.V104.11.4921.4921

Published: 2004

Journal Articles

Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.

Faith E. Davies, MD, J. Anthony Child, MD, Kim Hawkins, MSc, Susan Bell, DPhil, Julia Brown, MSc, Mark T. Drayson, PhD, Graham H. Jackson, PhD, Gareth J. Morgan, PhD

Blood (2004) 104 (11): 2395.

https://doi.org/10.1182/blood.V104.11.2395.2395

Published: 2004

Journal Articles

The Bone Marrow Microenvironment Influences the Differential Chemokine Receptor Expression of Normal and Neoplastic Plasma Cells.

Faith E. Davies, MD, Mona H. Al Rayes, J. Anthony Child, MD, Gareth J. Morgan, PhD, Andrew C. Rawstron, PhD

Blood (2004) 104 (11): 2353.

https://doi.org/10.1182/blood.V104.11.2353.2353

Published: 2004

Journal Articles

Serum Free Light Chain Levels in Asymptomatic Myeloma.

Bradley M. Augustson, MB;BS, Steven D. Reid, PhD, Graham P. Mead, PhD, Mark T. Drayson, PhD, J. Anthony Child, MD, Arthur R. Bradwell, MD

Blood (2004) 104 (11): 4880.

https://doi.org/10.1182/blood.V104.11.4880.4880

Published: 2004

Journal Articles

Early Mortality Following Diagnosis of Multiple Myeloma; Analysis of Patients Entered into the UK Medical Research Council Trials 1980–2002.

Bradley M. Augustson, MBBS, Gulnaz Begum, BSc, Nicola J. Barth, Cert Clin Res, Janet A. Dunn, PhD, Gareth J. Morgan, MD, J. Anthony Child, MD, Mark T. Drayson, PhD

Blood (2004) 104 (11): 3465.

https://doi.org/10.1182/blood.V104.11.3465.3465

Published: 2004

NARROW

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Rapid and Sensitive Detection of Minimal Plasma Cell Populations Using Six-Colour Flow Cytometry.

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

Correlation of Serum Free Light Chains and Bone Marrow Plasma Cell Infiltration in Multiple Myeloma.

Long-Term Survival in Patients Receiving Conventional Therapy for Newly Diagnosed Multiple Myeloma; Results from United Kingdom Medical Research Council Trials 1980–1997.

Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.

The Bone Marrow Microenvironment Influences the Differential Chemokine Receptor Expression of Normal and Neoplastic Plasma Cells.

Serum Free Light Chain Levels in Asymptomatic Myeloma.

Early Mortality Following Diagnosis of Multiple Myeloma; Analysis of Patients Entered into the UK Medical Research Council Trials 1980–2002.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only